



Immunomodulatory Effects of Drugs for Cancer Immunotherapy

Guest Editors:

Dr. Maiko Matsushita

Division of Clinical Physiology
and Therapeutics Keio University
Faculty of Pharmacy 1-5-30,
Shiba-koen, Minato-ku, Tokyo
105-8512, Japan

Dr. Takeshi Suzuki

Division of Basic Biological
Science, Faculty of Pharmacy,
Keio University, Tokyo 105-8512,
Japan

Deadline for manuscript
submissions:

closed (31 March 2023)

Message from the Guest Editors

Dear Colleagues,

Recent advances in cancer immunotherapy, including those in immune checkpoint inhibitors (ICIs) or adoptive T-cell therapies, have contributed to better outcomes in cancer patients. However, even ICIs are ineffective in the treatment of certain cancers. Therefore, new strategies to enhance the efficacy of treatments are needed. It has been reported that several commonly used drugs, such as statin, exert immune-modulatory effects; due to such properties, these drugs are expected to enhance the body's immunity against cancer cells.

This Special Issue aims to further develop the current body of literature on the current knowledge regarding the immunomodulatory effects of a wide variety of drugs, which will aid the advancement and development of cancer therapy.

We are inviting submissions of review or original articles on all aspects of “Immunomodulatory Effects of Drugs for Cancer Immunotherapy”.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma